Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 9 (7) |
| Completed vs Stopped Early | 6 / 1 (5.9%) |
| Median Closed Actual Enrollment | 141 participants |
| Physical Hospital Site Disclosure | 43.1% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Shanghai Chest Hospital | Shanghai | 3 |
| Peking University People's Hospital | Beijing, Beijing Municipality | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05504083 | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the InventisBio Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.